Changes in bronchial mucous membrane depending on the stage of COPD (I, II) Source: Annual Congress 2011 - COPD mechanisms Year: 2011
Factors affecting smear and culture conversion durations of category I, II and IV tuberculosis patients Source: Eur Respir J 2004; 24: Suppl. 48, 649s Year: 2004
Collagen I, III and IV content in airways and lung parenchyma of COPD patients Source: Annual Congress 2010 - Proteases and the matrix Year: 2010
Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III development Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
New induction (Ind), gemcitabine (G), docetaxel (D) and cisplatin (C) followed by concomitant (Con) chemoradiotherapy in stage IIIB non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008
Polymorphisms in the type IV collagen alpha3 gene and the risk of COPD Source: Eur Respir J 2008; 32: 35-41 Year: 2008
The relationship between PBMC secretion of IFN-alpha following stimulation by Poly (I:C) and clinical indices in COPD Source: Annual Congress 2010 - Colonisation and infection in COPD Year: 2010
Polymorphisms of the vitamin D receptor(VDR ) gene, collagen type I alpha 1(COLIA1 ) gene in Polish sarcoidosis patients Source: Eur Respir J 2007; 30: Suppl. 51, 114s Year: 2007
Inhibitor of DNA-binding (Id) – 1 and 3 proteins overexpression has impact on prognosis of lung adenocarcinoma Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Are we missing asthma COPD overlap (ACO) diagnosis among patient with COPD?Alameeri Amel(1), Dudina Alexandra(1) , Stephen Lane(1), Kennedy Merian(2) Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification Year: 2019
Carboplatin (C), paclitaxel (T) and etoposide (E) and early concurrent thoracic radiotherapy (TRT) for patients with limited disease small cell lung cancer (LD-SCLC): a Dutch multicentre phase 2 study Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002
Recombinant human pentraxin-2 for idiopathic pulmonary fibrosis: Design of STARSCAPE-OLE, a Phase III open label extension study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021
Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: Two phase 1 studies Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014
The influence of roflumilast on the IV-type collagen level in patients with III stage COPD Source: Annual Congress 2012 - Lung injury and repair: reactive oxygen species and beyond Year: 2012
Stage IV sarcoidosis: comparison of survival with the general population and causes of death Source: Eur Respir J 2011; 38: 1368-1373 Year: 2011
The relationship of vitamin D binding protein polymorphisms with blood vitamin D Level in Korean patients with COPD Source: International Congress 2015 – Genetics and environmental factors in phenotypes of asthma and COPD Year: 2015
Expression of transforming growth factors beta (1, 2, 3) and connective tissue growth factor in the peripheral lung from GOLD stage 1-2 COPD patients and smokers with normal lung function Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006